Macelignan inhibits macrophage M2 polarization via the ROS-mediated PI3K/AKT signaling pathway, thereby blocking IL-1β/NF-κB-dependent CRC metastasis (168). The gene discussed is AKT1; the disease is colorectal carcinoma.